XML 63 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated statements of changes in equity - EUR (€)
€ in Millions
Total
Attributable to equity holders of Sanofi 
Share capital
Additional paid-in capital
Treasury shares
Reserves and retained earnings
Stock options and other share- based payments
Other comprehensive income
Attributable to non- controlling interests
Beginning balance at Dec. 31, 2021 € 69,031 € 68,681 € 2,527 € 532 € (939) € 63,013 € 4,405 € (857) € 350
Other comprehensive income for the period 2,764 2,759       451   2,308 5
Net income for the period 8,484 [1] 8,371       8,371     113
Comprehensive income 11,248 11,130       8,822   2,308 118
Dividend paid out of earnings (4,168) (4,168)       (4,168)      
Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi [2] 793 793       793      
Payment of dividends to non-controlling interests (100) 0             (100)
Share repurchase program [3] (497) (497)     (497)        
Reduction in share capital [3] 0   (13) (587) 600 0      
Share-based payment plans:                  
Exercise of stock options 35 [3] 35 [3] 1 34 [3]          
Issuance of restricted shares and vesting of existing restricted shares [3],[4] 0 0 3 (3) 130 (130)      
Employee share ownership plan [3] 153 153 4 149          
Value of services obtained from employees 245 245         245    
Tax effects on share-based payments 8 8         8    
Other changes in non-controlling interests(d) (10) (10)       (10)      
Ending balance at Dec. 31, 2022 € 75,152 74,784 2,522 125 (706) 66,734 4,658 1,451 368
Share-based payment plans:                  
Dividends paid, ordinary shares per share (in EUR per share) € 3.33                
Other comprehensive income for the period € (1,603) (1,590)       (77)   (1,513) (13)
Net income for the period 5,436 [1] 5,400       5,400     36
Comprehensive income 3,833 3,810       5,323   (1,513) 23
Dividend paid out of earnings (4,454) (4,454)       (4,454)      
Payment of dividends to non-controlling interests (59) 0             (59)
Share repurchase program [3] (593) (593)     (593)        
Exercise of stock options [3] 37 37 1 36          
Issuance of restricted shares and vesting of existing restricted shares [3],[4] 0 0 3 (3) 115 (115)      
Employee share ownership plan [3] 159 159 4 155          
Value of services obtained from employees 283 283         283    
Tax effects on share-based payments 3 3         3    
Other changes arising from issuance of restricted shares [5] 2 2       2      
Other changes in non-controlling interests 0 (1)       (1)     1
Other changes in non-controlling interests [6] (10) 9       9     (19)
Ending balance at Dec. 31, 2023 € 74,353 74,040 2,530 313 (1,184) 67,499 4,944 (62) 313
Share-based payment plans:                  
Dividends paid, ordinary shares per share (in EUR per share) € 3.56                
Other comprehensive income for the period € 2,432 2,410       (28)   2,438 22
Net income for the period 5,618 5,560       5,560     58
Comprehensive income 8,050 7,970       5,532   2,438 80
Dividend paid out of earnings (4,704) (4,704)       (4,704)      
Payment of dividends to non-controlling interests (44) 0             (44)
Share repurchase program [3] (302) (302)     (302)        
Reduction in share capital [3] 0 0 (12) (492) 530 (26)      
Exercise of stock options [3] 33 33 1 32          
Issuance of restricted shares and vesting of existing restricted shares [3],[4] 0 0 3 (3) 116 (116)      
Employee share ownership plan [3] 154 154 4 150          
Value of services obtained from employees 305 305         305    
Tax effects on share-based payments 11 11         11    
Other changes arising from issuance of restricted shares [5] 1 1       1      
Ending balance at Dec. 31, 2024 € 77,857 € 77,507 € 2,526 € 0 € (840) € 68,185 € 5,260 € 2,376 € 350
Share-based payment plans:                  
Dividends paid, ordinary shares per share (in EUR per share) € 3.76                
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] This amount includes the valuation of the shares distributed as a dividend in kind, at a price of €14.58 per share, as of May 10, 2022 (see Note D.1.3).
[3] See Notes D.15.1., D.15.3., D.15.4. and D.15.5.
[4] This line includes the use of existing shares to fulfill vested rights under restricted share plans.
[5] This line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control
of EUROAPI.
[6] This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.